Overview

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The study was a local multicentric, open-label, non-randomized phase II study of nilotinib as a first line treatment in adult patients with newly-diagnosed Philadelphia chromosome-positive (Ph+) and chronic phase myeloid leukemia (CML-CP).
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals